These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 19820754

  • 1. [The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].
    Morales E, Huerta A, Gutiérrez E, Gutiérrez Solís E, Segura J, Praga M.
    Nefrologia; 2009; 29(5):421-9. PubMed ID: 19820754
    [Abstract] [Full Text] [Related]

  • 2. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, Bernis C, Espinosa M, Ahijado F, Gómez J, Escalada P.
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [Abstract] [Full Text] [Related]

  • 3. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E, Gutiérrez E, Caro J, Sevillano A, Rojas-Rivera J, Praga M.
    Nefrologia; 2015 Dec; 35(6):554-61. PubMed ID: 26519114
    [Abstract] [Full Text] [Related]

  • 4. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF.
    Cochrane Database Syst Rev; 2014 Apr 29; (4):CD007004. PubMed ID: 24782282
    [Abstract] [Full Text] [Related]

  • 5. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep 29; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 6. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K, Hayashi K, Kanda T, Yoshioka K, Takamatsu I, Tatematsu S, Kumagai H, Wakino S, Saruta T.
    J Hum Hypertens; 2004 Dec 29; 18(12):879-84. PubMed ID: 15295613
    [Abstract] [Full Text] [Related]

  • 7. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y, Takenaka T, Nakamura T, Suzuki H.
    Clin J Am Soc Nephrol; 2006 Jul 29; 1(4):730-7. PubMed ID: 17699280
    [Abstract] [Full Text] [Related]

  • 8. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul 29; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 9. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
    Bianchi S, Bigazzi R, Campese VM.
    Am J Kidney Dis; 2005 Jul 29; 46(1):45-51. PubMed ID: 15983956
    [Abstract] [Full Text] [Related]

  • 10. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
    Kincaid-Smith P, Fairley KF, Packham D.
    Nephrol Dial Transplant; 2004 Sep 29; 19(9):2272-4. PubMed ID: 15252156
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic measures in proteinuric nephropathy.
    Praga M.
    Kidney Int Suppl; 2005 Dec 29; (99):S137-41. PubMed ID: 16336567
    [Abstract] [Full Text] [Related]

  • 12. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF.
    Cochrane Database Syst Rev; 2009 Jul 08; (3):CD007004. PubMed ID: 19588415
    [Abstract] [Full Text] [Related]

  • 13. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
    González Monte E, Andrés A, Polanco N, Toribio MJ, Santana R, Gutiérrez Martínez E, González J, Ramírez E, Hernández A, Morales E, Praga M, Morales JM.
    Transplant Proc; 2010 Oct 08; 42(8):2899-901. PubMed ID: 20970564
    [Abstract] [Full Text] [Related]

  • 14. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
    Mori-Takeyama U, Minatoguchi S, Murata I, Fujiwara H, Ozaki Y, Ohno M, Oda H, Ohashi H.
    Clin Exp Nephrol; 2008 Feb 08; 12(1):33-40. PubMed ID: 18175062
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA, CHARM Investigators.
    Eur J Heart Fail; 2008 Feb 08; 10(2):157-63. PubMed ID: 18242128
    [Abstract] [Full Text] [Related]

  • 16. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
    Ferrari P, Marti HP, Pfister M, Frey FJ.
    J Hypertens; 2002 Jan 08; 20(1):125-30. PubMed ID: 11791035
    [Abstract] [Full Text] [Related]

  • 17. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
    Knudsen ST, Andersen NH, Poulsen SH, Eiskjaer H, Hansen KW, Helleberg K, Poulsen PL, Mogensen CE.
    Am J Hypertens; 2008 Feb 08; 21(2):172-6. PubMed ID: 18188164
    [Abstract] [Full Text] [Related]

  • 18. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 08; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 19. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
    Kim HY, Bae EH, Ma SK, Kim SW.
    Kidney Blood Press Res; 2014 Jan 08; 39(6):573-80. PubMed ID: 25531940
    [Abstract] [Full Text] [Related]

  • 20. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
    Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosoya T.
    Hypertens Res; 2002 Nov 08; 25(6):849-55. PubMed ID: 12484508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.